SCHEMBL23927445

SCHEMBL23927445

CCOC(=O)c1nnc(Cc2cc(F)cc(F)c2)[nH]1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 1/20 0.43
TSHR P16473 2/20 0.41
ALDH1A1 P00352 6/20 0.40
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
KDM4E B2RXH2 3/20 0.40
HPGD P15428 2/20 0.40
HTT P42858 1/20 0.40
RECQL P46063 1/20 0.40
ALOX5 P09917 2/20 0.38
PTGES O14684 1/20 0.38
MMP1 P03956 1/20 0.38
MMP2 P08253 1/20 0.38
MMP9 P14780 1/20 0.38
MMP12 P39900 1/20 0.38
MAPT P10636 2/20 0.38
LMNA P02545 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30091457 0.93 TSHR (0.39) NTRK1TSHRALDH1A1KMT2AMEN1
SCHEMBL23927479 0.93 TSHR (0.39) NTRK1TSHRALDH1A1KMT2AMEN1
SCHEMBL23927435 0.91 PDE3B (0.39) NTRK1TSHRALDH1A1KMT2AMEN1
SCHEMBL30091704 0.91 PDE3B (0.39) NTRK1TSHRALDH1A1KMT2AMEN1
SCHEMBL18420957 0.90 ALDH1A1 (0.39) NTRK1TSHRALDH1A1KMT2AMEN1
SCHEMBL23927471 0.88 GPR52 (0.39) NTRK1TSHRALDH1A1KMT2AMEN1
SCHEMBL30091622 0.88 GPR52 (0.39) NTRK1TSHRALDH1A1KMT2AMEN1
SCHEMBL19207821 0.87 PGR (0.39) NTRK1TSHRALDH1A1KMT2AMEN1
SCHEMBL29415696 0.87 PGR (0.39) NTRK1TSHRALDH1A1KMT2AMEN1
SCHEMBL23927492 0.87 ALDH1A1 (0.39) TSHRALDH1A1KMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435060-B2 Acylamino bridged heterocyclic compound, and composition and application thereof BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2025-10-07 US disclosed
EP-3901147-B1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) 2023-11-22 EP disclosed
US-20230026425-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-01-26 US disclosed
CN-113166116-B Amido bridged heterocyclic compound, and composition and application thereof 北京赛特明强医药科技有限公司 2022-12-27 CN disclosed
EP-3901147-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2021-10-27 EP disclosed
CN-113166116-A Amido bridged heterocyclic compound, and composition and application thereof 北京赛特明强医药科技有限公司 2021-07-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230026425-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF RIPK1, RIPK3, RIPK4 NTRK1 130/4885TSHR 2607/4885ALDH1A1 4164/4885
US-12435060-B2 Acylamino bridged heterocyclic compound, and composition and application thereof RIPK1, RIPK3, RIPK4 NTRK1 130/4885TSHR 2607/4885ALDH1A1 4164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.